Scythian happy with U.K. le­gal­iza­tion of med­i­cal pot

Scythian Bio­sciences Corp. is pleased with the U.K.’s de­ci­sion to le­gal­ize med­i­cal pot.

Stockwatch Daily - - FRONT PAGE - Mr. Brady Cobb re­ports

SCYTHIAN BIO­SCIENCES Corp. ap­plauds the United King­dom’s de­ci­sion to al­low spe­cial­ist doc­tors the op­tion to legally is­sue pre­scrip­tions for cannabis-based medicines when they be­lieve pa­tients could ben­e­fit from the treat­ment. Spe­cial­ist doc­tors in Eng­land, Wales and Scot­land will be able to pre­scribe cannabis-de­rived medicines in less than a month.

The law change, passed in Par­lia­ment yes­ter­day, came af­ter Home Sec­re­tary Sa­jid Javid lis­tened to con­cerns from par­ents of chil­dren with con­di­tions such as se­vere epilepsy. Over the sum­mer an ur­gent re­view of cannabis-based medic­i­nal prod­ucts was called fol­low­ing an out­cry over two young epilepsy suf­fer­ers, Al­fie Din­g­ley and Billy Cald­well, be­ing de­nied ac­cess to cannabis oil. “Con­grat­u­la­tions to the U.K. govern­ment and Home Sec­re­tary Sa­jid Javid, and a spe­cial con­grat­u­la­tions to our own chief med­i­cal of­fi­cer, Michael Barnes, whose years of work, col­lab­o­ra­tive ef­forts with mem­bers of govern­ment and in­sa­tiable ded­i­ca­tion to le­gal­iz­ing medic­i­nal cannabis use helped make this de­ci­sion oc­cur,” said chief ex­ec­u­tive of­fi­cer Brady Cobb. “Scythian is proud to have you as a se­nior leader of our team and strongly sup­ports your on­go­ing ini­tia­tives.”

Prof. Michael Barnes, a lead­ing world au­thor­ity in neu­ro­log­i­cal re­ha­bil­i­ta­tion and an in­flu­en­tial leader in the med­i­cal cannabis sec­tor, has been a pow­er­ful ad­vo­cate for the med­i­cal use of cannabis in the United King­dom. Through strate­gic re­la­tion­ships and key or­ga­ni­za­tions such as the End Our Pain web­site, the United Pa­tients Al­liance and Clear, as well as his par­tic­i­pa­tion in the drug pol­icy in­no­va­tion hub Volte­face, Prof. Barns has helped fa­cil­i­tate the ac­com­plish­ment of key mile­stones along the U.K.’s path to le­gal­iz­ing cannabis-de­rived medicines. One such mile­stone was reached this past July when Al­fie Din­g­ley be­came the first per­son in the U.K. to re­ceive a long-term li­cence to be treated with medic­i­nal cannabis. Prof. Barnes has lec­tured ex­ten­sively on med­i­cal cannabis use across the globe, in ad­di­tion to record­ing sev­eral live TV, ra­dio, print and so­cial me­dia in­ter­views on the topic. He has played an in­stru­men­tal part in Sa­jid Javid’s ground­break­ing de­ci­sion to loosen reg­u­la­tions on pre­scrib­ing med­i­cal cannabis in the U.K.

“This is a his­toric day,” said Prof. Barnes. “Many peo­ple have cam­paigned for many years to get to this point. We still have a way to go, par­tic­u­larly for doc­tors’ ed­u­ca­tion, but nev­er­the­less begin­ning in Novem­ber many tens of thou­sands of peo­ple with a whole range of med­i­cal con­di­tions can at last ac­cess a medicine that will surely ben­e­fit their health.”

About Scythian Bio­sciences Corp.

Scythian is an in­ter­na­tional cannabis com­pany with a fo­cus on le­gal U.S. states. Its strate­gic in­vest­ments and part­ner­ships across cul­ti­va­tion, dis­tri­bu­tion and re­tail com­ple­ment the com­pany’s re­search and devel­op­ment pro­gram with the Univer­sity of Mi­ami. It is this com­pre­hen­sive ap­proach that is positioning Scythian as a fu­ture fron­trun­ner in the United States med­i­cal cannabis in­dus­try.

We seek Safe Har­bor.

Jonathan Ross Gil­bert, Gary Leong, Ra­jiv Rai, Rob Reid, Ge­orge Scor­sis

(SCYB) Shares: 49,037,218

Newspapers in English

Newspapers from Canada

© PressReader. All rights reserved.